Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies

Zhen Yong Keck, Ta Kai Li, Jinming Xia, Meital Gal-Tanamy, Oakley Olson, Sophia H. Li, Arvind H. Patel, Jonathan K. Ball, Stanley M. Lemon, Steven K.H. Foung

Research output: Contribution to journalArticlepeer-review

105 Scopus citations

Abstract

Development of a successful hepatitis C virus (HCV) vaccine requires the definition of neutralization epitopes that are conserved among different HCV genotypes. Five human monoclonal antibodies (HMAbs) are described that cross-compete with other antibodies to a cluster of overlapping epitopes, previously designated domain B. Each HMAb broadly neutralizes retroviral pseudotype particles expressing HCV E1 and E2 glycoproteins, as well as the infectious chimeric genotype 1a and genotype 2a viruses. Alanine substitutions of residues within a region of E2 involved in binding to CD81 showed that critical E2 contact residues involved in the binding of representative antibodies are identical to those involved in the binding of E2 to CD81.

Original languageEnglish
Pages (from-to)6061-6066
Number of pages6
JournalJournal of Virology
Volume82
Issue number12
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Dive into the research topics of 'Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies'. Together they form a unique fingerprint.

Cite this